Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

MSC4381 is an inhibitor of monocarboxylate transporter 4 (MCT4; Ki = 0.011 µM).1 It selectively inhibits lactate efflux in MDA-MB-231 cells, which endogenously express high levels of MCT4, over SNU-398 cells, which endogenously express high levels of MCT1, and RT4 cells, which endogenously express MCT2 and MCT3 (IC50s = 0.001, >4, and 0.638 µM, respectively). MSC4381 (30 mg/kg) increases survival and reduces tumor volume in an MC-38 murine colorectal carcinoma model when administered in combination with an antibody targeting programmed cell death ligand 1 (PD-L1).2
WARNING This product is not for human or veterinary use.
1. Discovery of 5-
2. MCT4 blockade increases the efficacy of immune checkpoint blockade. J. Immunother. Cancer 11(10), e007349 (2023).